GBIM:OTCMKTS
GlobeImmune Inc
0,00010 US$
0,00%
(0,00) 1D
29. 9., 15:48:52 GMT-4 · USD
search
Všechny symboly
| Symbol | Cena | Změna | Změna (%) |
|---|
insights_autoGenerování hlavních statistik pro GBIM…
Trž. kap.
580,00
Prům. obj.
1,74 tis.
Objem
0,00
52týd. max.
0,04 US$
52týd. min.
0,00 US$
Akcie v oběhu
5,75 mil.
Počet zaměstnanců
22
Trž. kap.
580,00
Prům. obj.
1,74 tis.
Objem
0,00
52týd. max.
0,04 US$
52týd. min.
0,00 US$
Akcie v oběhu
5,75 mil.
Počet zaměstnanců
22
Zpravodajské články
Z webových zdrojů a od partnerů z oblasti zpravodajství
AskTraders.com
·
před 9 minutami
S&P 500: Why UBS Says Investors Should ‘Stay Invested Near Record Highs’
Yahoo Finance
·
před 1 hodinou
Beyond S&P 500 Index Funds: Here's the 1 Sector I'd Buy First as a New Investor
Benzinga
·
před 1 hodinou
Dow Jones, S&P 500, Nasdaq 100 Outlook: Top Stock Market News This Week
24/7 Wall St.
·
před 5 hodinami
KLA Turned $1,000 Into $31,595 in a Decade, Crushing the S&P 500 by 8.7x
Profil
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.
As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
Informace o GlobeImmune Inc
Generální ředitel-
Zaměstnanci22
Založeno1. 1. 1995
ÚstředíLouisville, Colorado, Spojené státy americké
Odvětví-